The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
This acquisition strengthens Lupin's commitment to providing superior treatment options for patients navigating the complexities of diabetes
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
The cash consideration for the above acquisition will be Euro 26 million.
The two generic drugs have been launched under the brand names Jankey & Sitenali.
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Phablecare closed this acquisition for an undisclosed sum, betting on the start-up's holistic approach to Type 1 Diabetes management
Subscribe To Our Newsletter & Stay Updated
